Gilead raised its full-year product sales guidance in its third-quarter 2026 update. The digest does not specify the revised guidance range or quantify the change. The update also described a larger projected GAAP loss tied to acquired R&D charges, but provided no amount in the report.
Key facts
Gilead raised its full-year product sales guidance; the digest gives no revised amount. source
A projected Medicare cut to Biktarvy payments is expected in 2028. source